A dominant negative type I insulin-like growth factor receptor inhibits metastasis of human cancer cells.
about
On how CCN6 suppresses breast cancer growth and invasionCelecoxib analogues disrupt Akt signaling, which is commonly activated in primary breast tumoursInhibition of CCN6 (WISP3) expression promotes neoplastic progression and enhances the effects of insulin-like growth factor-1 on breast epithelial cells.Implications of Insulin-like Growth Factor 1 Receptor Activation in Lung CancerTargeting insulin and insulin-like growth factor signaling in breast cancerReview on molecular and chemopreventive potential of nimbolide in cancerDoes growth hormone cause cancer?Potentiating the efficacy of molecular targeted therapy for hepatocellular carcinoma by inhibiting the insulin-like growth factor pathwayThe insulin-like growth factor-I receptor (IGF-IR) in breast cancer: biology and treatment strategies.Insulin-like growth factor I controls adhesion strength mediated by alpha5beta1 integrins in motile carcinoma cells.Obesity and breast cancer: a multipartite connection.Growth hormone and insulin-like growth factor-I in the transition from normal mammary development to preneoplastic mammary lesions.BMS-536924 reverses IGF-IR-induced transformation of mammary epithelial cells and causes growth inhibition and polarization of MCF7 cellsThe type I insulin-like growth factor receptor regulates cancer metastasis independently of primary tumor growth by promoting invasion and survival.Metabotropic glutamate receptor 1 mediates melanocyte transformation via transactivation of insulin-like growth factor 1 receptor.Inhibition of cancer cell proliferation and metastasis by insulin receptor downregulationNorthwestern profiling of potential translation-regulatory proteins in human breast epithelial cells and malignant breast tissues: evidence for pathological activation of the IGF1R IRES.Phosphorylation of the mutant K303R estrogen receptor alpha at serine 305 affects aromatase inhibitor sensitivityInsulin-like growth factors and neoplasia.Targeting 3-phosphoinoside-dependent kinase-1 to inhibit insulin-like growth factor-I induced AKT and p70 S6 kinase activation in breast cancer cells.Enhanced aggressiveness of benzopyrene-induced squamous carcinomas in transgenic mice overexpressing the proprotein convertase PACE4 (PCSK6).Bidirectional crosstalk between leptin and insulin-like growth factor-I signaling promotes invasion and migration of breast cancer cells via transactivation of epidermal growth factor receptorElevated insulin-like growth factor 1 receptor signaling induces antiestrogen resistance through the MAPK/ERK and PI3K/Akt signaling routes.The Role of the Insulin/IGF System in Cancer: Lessons Learned from Clinical Trials and the Energy Balance-Cancer Link.Enhancement of doxorubicin cytotoxicity of human cancer cells by tyrosine kinase inhibition of insulin receptor and type I IGF receptorType 1 Insulin-Like Growth Factor Receptor/Insulin Receptor Substrate 1 Signaling Confers Pathogenic Activity on Breast Tumor Cells Lacking REST.Engagement of β-arrestin by transactivated insulin-like growth factor receptor is needed for V2 vasopressin receptor-stimulated ERK1/2 activation.The therapeutic potential of agents targeting the type I insulin-like growth factor receptor.Treatment of hematologic malignancies and solid tumors by inhibiting IGF receptor signaling.The insulin-like growth factor-I receptor as a target for cancer therapy.Targeting the insulin-like growth factor axis as a cancer therapy.Multifaceted leptin network: the molecular connection between obesity and breast cancer.Targeting the insulin-like growth factor-1 receptor in human cancer.Insulin-like growth factor receptor inhibitors: baby or the bathwater?Small molecule inhibitors of IRES-mediated translation.Small molecule signal transduction inhibitors for the treatment of solid tumors.Insulin receptor substrate-2 regulates aerobic glycolysis in mouse mammary tumor cells via glucose transporter 1.Expression and function of the insulin receptor substrate proteins in cancerSequencing of type I insulin-like growth factor receptor inhibition affects chemotherapy response in vitro and in vivo.Differential roles of insulin-like growth factor receptor- and insulin receptor-mediated signaling in the phenotypes of hepatocellular carcinoma cells.
P2860
Q24598488-A8591857-76D3-4FE7-BD06-63BA268DE1A9Q24813725-5065FCFA-44AC-4B80-81FE-E47B734BFD0EQ25257817-1560BD0A-A7E1-4C11-8E1F-20AC0DF73821Q26740210-177B867F-7748-46FC-9712-27A5A9334727Q26826380-6ECAF3DF-045E-4D80-BACC-AD7AF7E0027CQ28082973-A801A411-5A79-4846-B6CB-91A933CF8584Q28293263-8FBEB6C6-6103-43D1-A42C-34992BB258CDQ28534009-6C589D6E-0D25-4D60-AF87-7CA730071652Q30244095-9ED46C7E-F6F5-43CA-B2C2-0C90DD799833Q33564187-2F1E9E3E-76EC-4222-BAC4-B531A0777B01Q33566125-F5FE3575-B54C-4780-9720-0CD21F566536Q33569159-A3B97EA9-5A45-4C6F-BF30-C859CBB79664Q33642235-6AD97320-9A09-4F31-BFAB-A02D884798A5Q33745823-DB449D41-7E8E-4B00-938F-D413E5E08356Q33769639-AA2E2546-1A8C-4F6C-9409-A42ECC51581FQ33818935-9172BC97-E0D4-4CD9-B2CD-22C94AB5EB33Q33843662-2950E6BC-42C5-434E-BF57-C22DECF90359Q34070890-5C3BB7AF-CA15-4A6F-84BD-BDD875C55803Q34330521-A8A25EB5-C15E-4E75-9260-FBBB79710CC6Q34465028-8E6880D6-FF86-4094-9AD2-D3E4E090A302Q34558009-3D865A9E-DA4D-4204-B9E0-16C3B54618C0Q35234141-917240D1-5770-4888-8CF7-D074579FAB49Q35558050-2AF4A8CF-82BC-4904-81CF-6A530E56E3E8Q35609517-E44C74D6-F69D-4FCD-ABBF-9333C3DD6083Q35910960-11319417-F6D0-4033-B801-C59C9BBBBB0EQ35917441-6A8C3AD2-CBE2-4E6C-B2C7-522F35F7747AQ35921791-71693839-077E-47F0-A06E-A2A4C54F799DQ35964712-2675741F-22A7-4DE2-8C9D-50D6136481E3Q36185627-F926D6D9-BFF3-4434-9238-2CB2CE433AC8Q36219706-A1BBEE20-C0F2-41C8-BF5E-7A9E1DF091ABQ36429684-8DE1B214-BD1E-4702-AF3F-5BE0252D8C1CQ36561207-53857223-C018-4C15-B6CE-74914A47B9DEQ36708178-980F0B18-489B-4E41-B71F-1715FD549401Q36790586-24CC52A4-9E3E-4E0B-AB40-26CC6F819E8AQ36838887-B32D47C3-DB1C-41A4-A307-2387C5DE9A9DQ36895413-4E403678-DD99-45A0-B92E-E9E0D34DB853Q37068060-B33F8287-DC7B-49AD-9BFC-158AACAE8ED7Q37257933-56409E0B-B800-4E8F-A04A-0D4F4E213F82Q37287624-B62F3846-8266-439F-9503-5F09D0928ADFQ37327775-7605B990-826C-4A97-883C-7AEA35F87258
P2860
A dominant negative type I insulin-like growth factor receptor inhibits metastasis of human cancer cells.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
A dominant negative type I ins ...... astasis of human cancer cells.
@en
type
label
A dominant negative type I ins ...... astasis of human cancer cells.
@en
prefLabel
A dominant negative type I ins ...... astasis of human cancer cells.
@en
P2093
P2860
P356
P1476
A dominant negative type I ins ...... tastasis of human cancer cells
@en
P2093
Adrian V Lee
Deepali Sachdev
Julie S Hartell
Xihong Zhang
P2860
P304
P356
10.1074/JBC.M305403200
P407
P50
P577
2003-11-13T00:00:00Z